Explore our core turnkey research protocols, validated active-ingredient extraction pathways, and Phase I–IV clinical validation models.
A technical treatise on transforming raw botanical variability into mathematically consistent, pharma-grade active substances through intelligent engineering and full regulatory traceability.
MedGence (Yineng Pharma), headquartered in Changsha, Hunan, acts as an institutional-grade CRO & CDMO bridgehead. With over 300 experienced research scientists, we have spearheaded modern chemical and pharmacological characterization for over 83 classical TCM formulas and engineered compliant manufacturing processes for nearly 400 single-herb monographs.
Transitioning beyond legacy batch processing, our China-based extraction infrastructure integrates continuous in-line NIR and multi-wavelength HPLC sensors. This provides real-time thermodynamic monitoring across cavitation, adsorption resin chromatography, membrane microfiltration, and vacuum freeze drying to lock batch consistency at a CV under 1.8%.
Under our contract manufacturing and trusted OEM protocols, our partners retain absolute exclusivity over proprietary structural analogs, novel solvent extraction blends, and finished dosage formulation kinetics. Enterprise firewalls, isolated cleanroom suites, and cGMP electronic record keeping ensure total intellectual asset protection.
How state-of-the-art Chinese smart biomanufacturing plants bypass conventional bottleneck limitations to deliver cost-superior, audit-ready chemical profiles.
Geographic sourcing variance accounts for up to 45% deviations in active phytochemical potency. Our supply ecosystem leverages satellite phenology data, historical climate soil indexing, and rapid HPLC field-testing to screen raw botanicals from authentic Dao-di production regions across China prior to industrial warehousing.
By implementing closed-loop Supercritical CO2 extraction, countercurrent ultrasonic-assisted extraction, and automated macroporous resin elution, we minimize thermal active degradation. This yields purity fractions unmatched by classical heat refluxing while slashing industrial solvent consumption by over 70%.
Operating adjacent to global transport hubs in Changsha and coastal freight lines, our facilities manage deep cold-chain integrity from pristine botanical harvesting to lyophilized finished active powders. This minimizes transit spoilage and supports tight lead times for global pharmaceutical brands.
Quantifiable milestones demonstrating deep collaboration with China's leading pharmaceutical entities, Tier-3 university clinical hospitals, and international regulatory reviewers.
A rigorous 6-stage operational pipeline engineered to de-risk high-value natural chemical programs from initial assay screening through commercial GMP dispatch.
Employing high-throughput bioassay screening, mass spectrometry (LC-MS/MS), and bioactivity mapping across varied plant matrices to isolate active target compounds (alkaloids, polyphenols, triterpenoid saponins).
Establishment of high-resolution HPTLC fingerprinting, validated reversed-phase HPLC assay methods, and GC-MS residual solvent thresholds compliant with USP, EP, and ChP guidelines.
Iterative optimization of milling granularity, solvent-to-solid ratios, dynamic extraction temps, resin column hydrodynamic mechanics, and spray drying parameters in our pilot production facilities.
Execution of GLP-compliant in vitro cellular receptor assays, Acute Toxicity (LD50), Ames test, in vitro micronucleus assays, and 28-day/90-day subchronic toxicity animal protocols.
GCP-aligned randomized double-blind placebo-controlled human trials for nutraceutical substantiation or Phase I–IV clinical designs for formal therapeutic new drug applications (NDA).
Full-scale commercial manufacturing across cGMP suites: concentrated liquids, microencapsulated extracts, freeze-dried powders, softgels, vegetarian capsules, and functional effervescent granules.
Our extraction engineering and customized dosage forms comply with evolving international safety directives across North America, the European Union, Japan, and Southeast Asia.
Demand centers on highly bioavailable, taste-masked botanical extracts with guaranteed active marker levels (e.g., Ginsenosides, Curcuminoids, Berberine). We deliver water-dispersible granules, high-density tableting powders, and ready-to-drink functional liquid shots meeting FSMA and EU Food Supplement Directives.
For research labs and multinational bio-pharma entities pursuing botanical INDs or NDA registrations. We supply high-purity single isolates (>98% by HPLC), chromatographic impurity profiles, elemental heavy metal removal (<0.1 ppm via ICP-MS), and ICH Q1A accelerated stability documentation.
Supplying clean-label active complexes with verified tyrosinase inhibition, anti-inflammatory cytokine suppression, or elastase inhibition. Formats include alcohol-free botanical extracts, liposomal encapsulated dispersions, and microfiltered essential oils adhering to the International Nomenclature of Cosmetic Ingredients (INCI).
Our extraction parameters, chemistry assays, and pilot formulations are relied upon by Tier-1 listed conglomerates and elite medical university research systems.
In-depth responses addressing technical compliance, supply chain safety margins, assay methodologies, and analytical transfers.
Directly commission validated pilot extraction studies, toxicity validation files, or commercial batch production through our Changsha facilities.
